|
Re: Resverlogix Expands Phase 2b Clinical Trial for COVID-19
|
10
|
Resverlogix Corp.
|
Feb 17, 2022 12:31PM
|
|
Re: Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
|
5
|
Resverlogix Corp.
|
Oct 23, 2015 03:37PM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
6
|
Resverlogix Corp.
|
Sep 06, 2017 04:59PM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
2
|
Resverlogix Corp.
|
Sep 05, 2017 10:35AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
2
|
Resverlogix Corp.
|
Sep 07, 2017 09:19AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
3
|
Resverlogix Corp.
|
Sep 05, 2017 01:50PM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
1
|
Resverlogix Corp.
|
Sep 05, 2017 02:47PM
|
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
7
|
Resverlogix Corp.
|
Jun 22, 2022 10:30AM
|
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
4
|
Resverlogix Corp.
|
Jun 27, 2022 07:35PM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
1
|
Resverlogix Corp.
|
Sep 30, 2019 04:34PM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
1
|
Resverlogix Corp.
|
Sep 30, 2019 09:05AM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
2
|
Resverlogix Corp.
|
Sep 30, 2019 09:57AM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
2
|
Resverlogix Corp.
|
Sep 30, 2019 10:31AM
|
|
Re: RESVERLOGIX ANNOUNCES PUBLICATION OF KEY APABETALONE STUDY BETONMACE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
|
5
|
Resverlogix Corp.
|
Mar 31, 2020 05:52PM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
12
|
Resverlogix Corp.
|
Apr 20, 2022 11:51AM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
6
|
Resverlogix Corp.
|
Jun 13, 2023 09:08AM
|
|
Re: Resverlogix Announces Lifting by TSX of Review
|
2
|
Resverlogix Corp.
|
May 11, 2018 03:48PM
|
|
Re: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
|
3
|
Resverlogix Corp.
|
Jun 06, 2017 03:37PM
|
|
Re: Resverlogix announces HEPALINK debenture $6mill
|
4
|
Resverlogix Corp.
|
May 05, 2021 11:07AM
|
|
Re: Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
|
3
|
Resverlogix Corp.
|
Jun 18, 2018 08:34PM
|
